| 货号 | 4401S |
| 供应商 | CST |
| 背景 | Crizotinib, also known as PF-02341066, is a novel, ATP-competitive receptor kinase inhibitor, showing high specificity for c-Met and anaplastic lymphoma kinase (ALK) over 120 other diverse kinases (1,2). Researchers have shown that crizotinib inhibits c-Met phosphorylation and c-Met-dependent proliferation, migration, and invasion of human tumor cells in vitro (IC50 values of 5–20 nM) (1). Crizotinib is effective against the constitutively active oncogenic fusion protein nucleophosmin (NPM)-ALK, inhibiting its phosphorylation (mean IC50 of 24 nM), inhibiting cell growth, and inducing G1-S phase cell cycle arrest and apoptosis in the ALK-positive ALCL (anaplastic large-cell lymphoma) cell lines KARPAS-299 and SU-DHL-1 (2). |
| 存放说明 | -20C |
| 参考文献 | 1 . Zou, H.Y. et al. (2007) Cancer Res 67, 4408-17. 2 . Christensen, J.G. et al. (2007) Mol Cancer Ther 6, 3314-22. |
Chemical structure of crizotinib.克唑替尼的化学结构。 | |
Western blot analysis of extracts from KARPAS-299 cells, untreated or treated with crizotinib (1 hr) at the indicated concentrations, using Phospho-ALK (Tyr1604) Antibody #3341 (upper) or ALK (D5F3) XP® Rabbit mAb #3633 (lower).Western blot方法检测KARPAS-299细胞提取物，细胞不处理或用指定浓度的克唑替尼（1 hr）处理，使用的抗体为Phospho-ALK (Tyr1604) Antibody #3341 (上图)或ALK (D5F3) XP® Rabbit mAb #3633 (下图). |
